Characteristics and Predictors of Venous Thromboembolism Among Lymphoma Patients Undergoing Chemotherapy: A Cohort Study in China.

Venous thromboembolism (VTE) is a potential complication among lymphoma patients. We evaluated the incidence rate and predictors of VTE in lymphoma patients undergoing chemotherapy. The present study retrospectively studied 1,069 patients with lymphoma who were treated with chemotherapy from 2018 to 2020. We investigated clinical predictors of VTE among all patients. The follow-up results were obtained telephone communication and from inpatient and outpatient records. A total of 1,069 patients underwent chemotherapy for lymphoma. During a mean follow-up of 23.1 months, 52 (4.9%) patients developed VTE. According to a multivariate analysis, the five variables found to be independently associated with VTE were male sex (HR 2.273, 95% CI 1.197-4.316, = 0.012), age >64-years-old (HR 2.256, 95% CI 1.017-5.005, = 0.045), the number of cycles of chemotherapy (HR 4.579, 95% CI 1.173-17.883, = 0.029), platelet count ≥350 × 10/L (HR 2.533, 95% CI 1.187-5.406, = 0.016), and D-dimer >0.5 mg/L (HR 4.367, 95% CI 2.124-8.981, < 0.001). This population-based study confirms the risk factors for VTE among patients with lymphoma who underwent chemotherapy and confirms that targeted thromboprophylaxis may reduce the burden of VTE in this population.